A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

Summary

This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.

Timeline

Start

2023-03-31

Primary completion

2026-06-30

Completion

2026-09-30

Drugs

Indications